Dyadic to Interview with FOX Business Network on Monday, January 27, 2020

January 27, 2020 8:00 AM

JUPITER, FL / ACCESSWIRE / January 27, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief...

Read more

Having trouble sleeping? cbdMD has you covered

January 24, 2020 7:50 PM

NEW YORK, NY / ACCESSWIRE / January 24, 2020 / Everyday we face a lot of stress and tension that it causes most of us to have a week or worse, a month of sleepless nights. All that tossing, turning, and staring at the ceiling almost every night can leave you feeling more tired and stressed the next day. It's estimated that 70 million people in the U.S. suffer from some form of sleeplessness. If you're one of those who's...

Read more

Mota Ventures Forms Research and Development Partnership with Leading Colombian University & Research Hospital

January 23, 2020 3:05 AM

VANCOUVER, BC / ACCESSWIRE / January 23, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the "Company") is pleased to announce that its wholly owned subsidiary Ihuana S.A.S ("Ihuana") has entered into a research cooperation agreement (the "Agreement") with La Fundacion Universitaria de Ciencias de la Salud (The University Foundation of Health Sciences) (the "University") located in Bogota,...

Read more

Experion Signs Non-Binding Term Sheet for Up To $8.5 Million Term Loan from Trichome Financial, a Leading Cannabis Focused Institutional Investor

January 22, 2020 8:45 AM

Debt Funding Targeted at Accelerating Growth and Capacity Expansion Initiatives VANCOUVER, BC / ACCESSWIRE / January 22, 2020 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) is pleased to announce that it has signed a non-binding term sheet (the "Term Sheet") to receive up to $8.5 million in the form of a senior secured term loan (the "Term Loan") from...

Read more

Experion Announces Returning Board Director

January 21, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / January 21, 2020 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) today announces the return of Sean MacNeil as director effective January 17, 2020. Mr. MacNeil took a leave from the Board early last summer to help his wife, Terri, work through her latest cancer treatment. With the support of Terri and his family, Mr. MacNeil has rejoined the Board...

Read more

Mota Schedules Investor Conference Call with First Class CBD Management

January 21, 2020 3:05 AM

VANCOUVER, BC / ACCESSWIRE / JANUARY 21, 2020 / MOTA VENTURES CORP. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the "Company" or "Mota Ventures") an emerging vertically integrated global CBD brand, is pleased to announce that due to the high volume of questions resulting from the Monday, January 20, 2020 investor conference call, the Company will host a follow-up investor conference call on January 29, 2020 at 1:15 pm (Vancouver...

Read more

Mota Schedules Investor Call Due to Volume of Inquiries

January 15, 2020 3:05 AM

VANCOUVER, BC / ACCESSWIRE / January 15, 2020 / MOTA VENTURES CORP. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the "Company" or "Mota Ventures") an emerging vertically integrated global CBD brand, is pleased to announce it will be hosting an investor conference call. Due to the significant number of inquiries from investors, Mota will be discussing recent announcements. The conference call will be held on Monday, January 20, 2020...

Read more

Xenetic Biosciences, Inc. Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen(R) Platform Technology

January 14, 2020 8:35 AM

- SHP656 program utilized Xenetic's PolyXen platform technology to conjugate polysialic acid to therapeutic blood-clotting factors - Phase 1/2 study demonstrated SHP656's efficacy and pharmacokinetic data commensurate with the profile of an extended half-life rFVIII product FRAMINGHAM, MA / ACCESSWIRE / January 14, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical...

Read more

Interface Biologics Announces Spinout, Ripple Therapeutics

January 14, 2020 8:00 AM

TORONTO, ON / ACCESSWIRE / January 14, 2020 / Following the sale of its surface modification business to Evonik (EVR:ETK), Interface Biologics Inc. ("IBI"), is pleased to announce the launch of Ripple Therapeutics Corporation ("Ripple"), a privately held, clinical stage developer of novel drugs. The Ripple Epidel technology is founded on a discovery that drugs can be engineered into controlled release Pharmaceuticals and...

Read more

Cutting Edge Immunotherapy for Peanut Allergy Presented at Biotech Showcase(TM) 2020

January 13, 2020 1:30 PM

SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2020 / Intrommune Therapeutics presented an update today on their oral mucosal immunotherapy (OMIT) technology at the Biotech Showcase™, which occurs during the annual J.P. Morgan Healthcare Conference. To view the full interactive, multimedia news release, click here. "We are very excited to provide investors an overview of our OMIT technology," said Michael Nelson, CEO,...

Read more

Pacylex Discusses new oncology target and drug candidate at Biotech Showcase: PCLX-001 is getting ready to enter clinical trials

January 9, 2020 9:05 AM

Presenting at the Biotech Showcase Monday, January 13, 2020, 4 pm PST at the Hilton San Francisco Union Square in San Francisco, California. EDMENTON, ALBERTA / ACCESSWIRE / January 9, 2020 / PACYLEX PHARMACEUTICALS, INC. a pre-IND-stage pharmaceutical company targeting hematologic cancers with a new first-in-class therapeutic, announced today that its chief executive officer, Michael Weickert, will present at the Biotech Showcase 2020...

Read more

A New Prescription Nasal Spray Providing Hope to Dementia Patients and their Carers

January 9, 2020 9:05 AM

Presenting at Sachs 3rd Neurosciences Innovation Forum Sunday, January 12, 2020 at 12:05 PM Marines' Memorial Club in San Francisco, California Presenting at Biotech Showcase Tuesday January 14, 2020 9:30 AM Hilton San Francisco Union Square in San Francisco, California. SAN FRANCISCO, CA / ACCESSWIRE / January 9, 2020 / LACHESIS BIOSCIENCES LTD, a clinical-stage biotechnology company targeting dementia caused by Alzheimer's and...

Read more

PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens announced today that its Chief Executive Officer, Alexander Belcredi, will present at the Biotech Showcase 2020 Conference

January 8, 2020 5:35 PM

Presenting at the Biotech Showcase, 2020 Tuesday, January 14, 2020 10:30 am PST PhagoMed's presentation at Biotech Showcase will cover its proprietary engineering platform, its lead assets and an outlook to the plans for 2020 and beyond VIENNA / ACCESSWIRE / January 8, 2020 / PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens in antibiotic resistance and microbiome settings,...

Read more

Cure Rare Disease: A Year in Review

January 8, 2020 9:00 AM

Significant Milestones Fuel Development of Customized Therapeutics for Duchenne muscular dystrophy BOSTON,MA / ACCESSWIRE / January 8, 2020 / Cure Rare Disease (CRD), the emerging, Boston-based nonprofit on a mission to develop precision medicine for rare diseases, is pleased to provide an annual review of its activities and accomplishments in 2019. Successful fundraising efforts have allowed CRD to accelerate their drug development plan,...

Read more

A Key Message from the New CEO, Jarrett Malnarick

January 8, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / January 8, 2020 / Experion Holdings Ltd. (the "Corporation" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) Given the recent leadership change announced on January 6, 2020, Experion Holdings Ltd.'s newly appointed CEO and Director, Jarret Malnarick, is pleased to share some immediate strategy and objectives going forward for the Company As the Canadian cannabis industry continues to...

Read more

Hancock Jaffe Reports Positive Results for 6 Month CoreoGraft Animal Feasibility Study

January 8, 2020 8:31 AM

Grafts Open and Fully Functional at 6 Months IRVINE, CA / ACCESSWIRE / January 8, 2020 / Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced positive results from its six (6) month CoreoGraft animal feasibility study. At thirty (30), ninety (90), and one hundred and eighty (180) days post CoreoGraft bypass surgeries, all grafts were patent (open) when the...

Read more

NanoValent Pharmaceuticals Announces the Publication of US Patent Targeted Polymerized Nanoparticles for Cancer Treatment

January 8, 2020 8:00 AM

NanoValent will Deliver a Corporate Presentation at the IvyFON Family Office 2020 Outlook Conference, January 14th in San Francisco during the JP Morgan Healthcare Conference Week SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2020 / NanoValent Pharmaceuticals, Inc., a development stage cancer focused pharmaceutical company progressing a new class of targeted nanospheres (TNS) based therapies today announced the publication of United States...

Read more

AML, Ewing Sarcoma, ARDS, HIV, IO, Phages, Infections, Diagnostics and Alzheimer’s; All ready to move to the next clinical level. All at the JP Morgan Healthcare Conference Week

January 8, 2020 8:00 AM

CHICAGO, IL / ACCESSWIRE / January 8, 2020 / Content Carnivores, LLC, a creative marketing firm deploying proprietary technology, category and creative expertise in regulated industries is supporting 10 clients who are participating at the Biotech Showcase™ 2020, investor conference and/or other events in San Francisco being held simultaneously as the JP Morgan Healthcare Conference, January 12 -16, 2020. To view the full release with...

Read more

Pieris Pharmaceuticals Announces Leadership Update

January 8, 2020 8:00 AM

BOSTON, MA / ACCESSWIRE / January 8, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced an update to its senior leadership team. Within research and development, Ingmar Bruns, M.D., Ph.D., previously serving as Vice President, Clinical...

Read more

Dyadic Reports Continued Positive Business Trends and Scientific Results in Fourth Quarter 2019

January 6, 2020 4:10 PM

Expanded ZAPI Program and Positive Preliminary Results from ZAPI Animal StudyNew Collaboration Agreement with Top Ten Pharmaceutical CompanyExpanded Research Relationship with Leading Pharmaceutical CompanyIIBR Collaboration Achieved Expression of Fc-fusion Enzyme to Counter Biological Attacks Glycoengineering Data Reinforces Company's Accelerated Glyco StrategyTwo New Patent ApplicationsJUPITER, FL / ACCESSWIRE / January 6, 2020 / Dyadic...

Read more